Search results
The murky, unregulated world of anti-ageing stem cell therapy
The Telegraph via Yahoo News· 2 days agoStem cells are the new focal point of the rich and famous with Hollywood A-listers reportedly...
At 6.48% CAGR, Vitrectomy Devices Market to Reach USD 2.05 Billion By 2031 Driven by Increasing...
Digital Journal· 10 hours agoThe global Vitrectomy Devices Market is set to witness a significant surge in valuation, projected...
The murky, unregulated world of anti-ageing stem cell therapy
Daily Telegraph· 2 days agoFor while there are very few evidence-based stem cell therapies which are officially approved by...
Health Care Roundup: Market Talk
The Wall Street Journal· 4 days agoMoreover, its planned launch of aflibercept—for patients living with wet macular degeneration—could be a potentially significant biosimilar opportunity,...
JD Supra: Regeneron v Novartis and Vetter: Walker Process Client Update
JD Supra· 1 day agoIn an appeal that attracted a dozen amici, including the Department of Justice, the Federal Trade Commission, five states, and the District of Columbia, the Second Circuit gave the Walker Process ...
Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment...
Morningstar· 2 days agoDALLAS, April 25, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical
Newswise Expert | Carl Awh, American Society of Retina Specialists
Newswise· 1 day agoCarl Awh, MD (pronounced "Oh") is the President of the Foundation of the American Society of Retina Specialists (ASRS) and Immediate Past President of ASRS. Dr. Awh is an internationally recognized ...
Belite Bio secures $25 million in registered direct offering By Investing.com
Investing.com· 1 day agoBelite Bio, Inc (NASDAQ: BLTE), a biopharmaceutical company specializing in degenerative retinal...
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC...
Morningstar· 4 days agoPreclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public
Saffron and sight: Study explores longer-term effects
Nutraingredients.com· 3 days agoAccording to a recent study published in BMJ Open Ophthalmology, 12 months of saffron...